CCM
SGTX

CAAS Capital Management’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

CAAS Capital Management’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,692
Closed -$782K – 1388
2021
Q1 		$782K Hold
2,692
– – 0.01% 843
2020
Q4 		$1.68M Buy
+2,692
New +$1.22M 0.02% 524

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAAS Capital Management's SGTX Position: Q2 2021 in Review

CAAS Capital Management sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2021, closing a stake of 2,692 shares — an estimated $782K sold.

CAAS Capital Management first reported a position in SGTX in Q4 2020 and held it in 2 quarters. The position peaked at $1.68M in Q4 2020. 52 funds tracked by Wall St. Rank hold SGTX as of Q2 2021.

  • CAAS Capital Management reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 2,692 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $782K.
  • CAAS Capital Management first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • CAAS Capital Management's Sigilon Therapeutics, Inc. Common Stock position peaked at $1.68M in Q4 2020.
  • 52 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.